The Experts below are selected from a list of 88332 Experts worldwide ranked by ideXlab platform
Joan K Morris - One of the best experts on this subject based on the ideXlab platform.
-
Survival of trisomy 18 edwards syndrome and trisomy 13 patau syndrome in england and wales 2004 2011
American Journal of Medical Genetics Part A, 2013Co-Authors: Jianhua Wu, Anna Springett, Joan K MorrisAbstract:The aim of this study is to determine the Survival of live births with trisomy 18 and trisomy 13 and their variants. Information on live births with trisomy 18 or trisomy 13 recorded in the National Down Syndrome Cytogenetic Register (NDSCR) was linked by the NHS Information Centre to obtain information about Survival. Survival was known for 326 (88%) of live births withtrisomy18and142(82%)oflivebirthswithtrisomy13born in England and Wales between 2004 and 2011. The Median Survival Time for live births with full trisomy 18 was 14 days and with full trisomy 13 was 10 days, the 3-month Survival was 20% and 18%, respectively, and the 1-year Survival for both syndromes was 8%. The 1-year Survival for live births with trisomy 18 mosaicism (n ¼ 17) was 70%, for those with trisomy 13mosaicism(n ¼ 5)was80%andforthosewithpartialtrisomy 13 (Robertsonian translocations) (n ¼ 17) was 29%. This study is based on the largest data set on Survival for live births with trisomy 18 and trisomy 13. Although Median Survival for these children is2weeksorless, about oneinfivesurvive for 3months ormore and about 1in 12 survive for 1year or more. We suggest that these Survival rates are used in counselling as well as the Median Survival Time. 2013 Wiley Periodicals, Inc.
-
Survival of trisomy 18 (Edwards syndrome) and trisomy 13 (Patau Syndrome) in England and Wales: 2004-2011.
American journal of medical genetics. Part A, 2013Co-Authors: Anna Springett, Joan K MorrisAbstract:The aim of this study is to determine the Survival of live births with trisomy 18 and trisomy 13 and their variants. Information on live births with trisomy 18 or trisomy 13 recorded in the National Down Syndrome Cytogenetic Register (NDSCR) was linked by the NHS Information Centre to obtain information about Survival. Survival was known for 326 (88%) of live births with trisomy 18 and 142 (82%) of live births with trisomy 13 born in England and Wales between 2004 and 2011. The Median Survival Time for live births with full trisomy 18 was 14 days and with full trisomy 13 was 10 days, the 3-month Survival was 20% and 18%, respectively, and the 1-year Survival for both syndromes was 8%. The 1-year Survival for live births with trisomy 18 mosaicism (n = 17) was 70%, for those with trisomy 13 mosaicism (n = 5) was 80% and for those with partial trisomy 13 (Robertsonian translocations) (n = 17) was 29%. This study is based on the largest data set on Survival for live births with trisomy 18 and trisomy 13. Although Median Survival for these children is 2 weeks or less, about one in five survive for 3 months or more and about 1 in 12 survive for 1 year or more. We suggest that these Survival rates are used in counselling as well as the Median Survival Time.
Penny K Sneed - One of the best experts on this subject based on the ideXlab platform.
-
gamma knife radiosurgery for brain metastases from primary breast cancer
International Journal of Radiation Oncology Biology Physics, 2007Co-Authors: Norbert Kased, William M Wara, Devin K Binder, Michael W Mcdermott, Jean L Nakamura, K Huang, Mitchel S Berger, Penny K SneedAbstract:Purpose The relative roles of stereotactic radiosurgery (SRS) vs. whole brain radiotherapy (WBRT) in the treatment of patients with brain metastases from breast cancer remain undefined. In this study, we reviewed our experience with these patients. Materials and Methods We retrospectively reviewed all patients treated between 1991 and 2005 with Gamma Knife SRS for brain metastases from breast cancer. The actuarial Survival and freedom from progression endpoints were calculated using the Kaplan-Meier method. Results Between 1991 and 2005, 176 patients underwent SRS for brain metastases from breast cancer. The Median Survival Time was 16.0 months for 95 newly diagnosed patients and 11.7 months for 81 patients with recurrent brain metastases. In the newly diagnosed patients, omission of upfront WBRT did not significantly affect the MST ( p = .20), brain freedom from progression ( p = .75), or freedom from new brain metastases ( p = .83). Longer Survival was associated with age Conclusion We have described prognostic factors for breast cancer patients treated with SRS for newly diagnosed or recurrent brain metastases. Most patient subsets had a Median Survival Time of ≥11 months. Unexpectedly, upfront WBRT did not appear to improve brain freedom from progression, and a larger number of brain metastases was not associated with a shorter Survival Time. Breast cancer might be distinct from other primary sites in terms of prognostic factors and the roles of WBRT and SRS for brain metastases.
-
phase ii study of high central dose gamma knife radiosurgery and marimastat in patients with recurrent malignant glioma
International Journal of Radiation Oncology Biology Physics, 2002Co-Authors: David A Larson, Vernon Smith, Kathleen R Lamborn, William M Wara, Penny K Sneed, Michael D Prados, Susan M Chang, Kelly M Nicholas, Daniel Devriendt, Sandeep KunwarAbstract:Abstract Purpose: To assess the outcome of high central dose Gamma Knife radiosurgery plus marimastat in patients with recurrent malignant glioma. Methods and Materials: Twenty-six patients with recurrent malignant glioma were enrolled in a prospective Phase II study between November 1996 and January 1999. The radiosurgery dose was prescribed at the 25–30% isodose surface to increase the dose substantially within the tumor's presumably hypoxic core. Marimastat was administered after radiosurgery to restrict regional tumor progression. Survival was compared with that of historical patients treated at our institution with standard radiosurgery. Results: The Median Times to progression after radiosurgery for Grade 3 and 4 patients was 31 and 15 weeks, respectively. The corresponding Median Survival Time after radiosurgery was 68 and 38 weeks. The Median Survival Time after radiosurgery in the historical patients was 59 and 44 weeks. Conclusion: The dual strategies of using high central dose radiosurgery to overcome tumor hypoxia together with marimastat to inhibit local tumor invasion may offer a small Survival advantage for recurrent Grade 3 tumors; they do not offer an advantage for recurrent Grade 4 tumors.
Sarah J Nelson - One of the best experts on this subject based on the ideXlab platform.
-
Survival analysis in patients with glioblastoma multiforme predictive value of choline to n acetylaspartate index apparent diffusion coefficient and relative cerebral blood volume
Journal of Magnetic Resonance Imaging, 2004Co-Authors: Joonmi Oh, Susan M Chang, Roland G Henry, Andrea Pirzkall, Ying Lu, Xiaojuan Li, I Catalaa, William P Dillon, Sarah J NelsonAbstract:Purpose To investigate the potential value of pre-external-beam radiation therapy (XRT) choline-to-NAA (N-acetylaspartate) index (CNI), apparent diffusion coefficient (ADC), and relative cerebral blood volume (rCBV) for predicting Survival in newly diagnosed patients with glioblastoma multiforme (GBM). Materials and Methods Twenty-eight patients with GBM were studied using in vivo proton magnetic resonance spectroscopic imaging (1H MRSI) and diffusion- and perfusion-weighted imaging after surgery but prior to XRT. Patients were categorized on the basis of their volumes of morphologic and metabolic abnormalities (volume of CNI ≥ 2 and CNI values), normalized ADC (nADC), or rCBV values within the T1 contrast-enhancing and T2 regions. The Median Survival Time was compared. Results A significantly shorter Median Survival Time was observed for patients with a large volume of metabolic abnormality than for those with a small abnormality (12.0 and 17.1 months, respectively, P = 0.002). A similar pattern was observed for patients with a low mean nADC value compared to those with high mean nADC value within the T2 region (11.2 and 21.7 months, respectively, P = 0.004). A shorter Median Survival Time was also observed for patients with contrast-enhancing residual disease than for those without the presence of contrast enhancement with marginal significance. Conclusion The pre-XRT volume of the metabolic abnormality and the nADC value within the T2 region may be valuable in predicting outcome for patients with GBM. J. Magn. Reson. Imaging 2004;19:546–554. © 2004 Wiley-Liss, Inc.
-
Survival analysis in patients with glioblastoma multiforme predictive value of choline to n acetylaspartate index apparent diffusion coefficient and relative cerebral blood volume
Journal of Magnetic Resonance Imaging, 2004Co-Authors: Joonmi Oh, Susan M Chang, Roland G Henry, Andrea Pirzkall, Ying Lu, Xiaojuan Li, I Catalaa, William P Dillon, Sarah J NelsonAbstract:PURPOSE: To investigate the potential value of pre-external-beam radiation therapy (XRT) choline-to-NAA (N-acetylaspartate) index (CNI), apparent diffusion coefficient (ADC), and relative cerebral blood volume (rCBV) for predicting Survival in newly diagnosed patients with glioblastoma multiforme (GBM). MATERIALS AND METHODS: Twenty-eight patients with GBM were studied using in vivo proton magnetic resonance spectroscopic imaging (1H MRSI) and diffusion- and perfusion-weighted imaging after surgery but prior to XRT. Patients were categorized on the basis of their volumes of morphologic and metabolic abnormalities (volume of CNI > or = 2 and CNI values), normalized ADC (nADC), or rCBV values within the T1 contrast-enhancing and T2 regions. The Median Survival Time was compared. RESULTS: A significantly shorter Median Survival Time was observed for patients with a large volume of metabolic abnormality than for those with a small abnormality (12.0 and 17.1 months, respectively, P = 0.002). A similar pattern was observed for patients with a low mean nADC value compared to those with high mean nADC value within the T2 region (11.2 and 21.7 months, respectively, P = 0.004). A shorter Median Survival Time was also observed for patients with contrast-enhancing residual disease than for those without the presence of contrast enhancement with marginal significance. CONCLUSION: The pre-XRT volume of the metabolic abnormality and the nADC value within the T2 region may be valuable in predicting outcome for patients with GBM.
Anna Springett - One of the best experts on this subject based on the ideXlab platform.
-
Survival of trisomy 18 edwards syndrome and trisomy 13 patau syndrome in england and wales 2004 2011
American Journal of Medical Genetics Part A, 2013Co-Authors: Jianhua Wu, Anna Springett, Joan K MorrisAbstract:The aim of this study is to determine the Survival of live births with trisomy 18 and trisomy 13 and their variants. Information on live births with trisomy 18 or trisomy 13 recorded in the National Down Syndrome Cytogenetic Register (NDSCR) was linked by the NHS Information Centre to obtain information about Survival. Survival was known for 326 (88%) of live births withtrisomy18and142(82%)oflivebirthswithtrisomy13born in England and Wales between 2004 and 2011. The Median Survival Time for live births with full trisomy 18 was 14 days and with full trisomy 13 was 10 days, the 3-month Survival was 20% and 18%, respectively, and the 1-year Survival for both syndromes was 8%. The 1-year Survival for live births with trisomy 18 mosaicism (n ¼ 17) was 70%, for those with trisomy 13mosaicism(n ¼ 5)was80%andforthosewithpartialtrisomy 13 (Robertsonian translocations) (n ¼ 17) was 29%. This study is based on the largest data set on Survival for live births with trisomy 18 and trisomy 13. Although Median Survival for these children is2weeksorless, about oneinfivesurvive for 3months ormore and about 1in 12 survive for 1year or more. We suggest that these Survival rates are used in counselling as well as the Median Survival Time. 2013 Wiley Periodicals, Inc.
-
Survival of trisomy 18 (Edwards syndrome) and trisomy 13 (Patau Syndrome) in England and Wales: 2004-2011.
American journal of medical genetics. Part A, 2013Co-Authors: Anna Springett, Joan K MorrisAbstract:The aim of this study is to determine the Survival of live births with trisomy 18 and trisomy 13 and their variants. Information on live births with trisomy 18 or trisomy 13 recorded in the National Down Syndrome Cytogenetic Register (NDSCR) was linked by the NHS Information Centre to obtain information about Survival. Survival was known for 326 (88%) of live births with trisomy 18 and 142 (82%) of live births with trisomy 13 born in England and Wales between 2004 and 2011. The Median Survival Time for live births with full trisomy 18 was 14 days and with full trisomy 13 was 10 days, the 3-month Survival was 20% and 18%, respectively, and the 1-year Survival for both syndromes was 8%. The 1-year Survival for live births with trisomy 18 mosaicism (n = 17) was 70%, for those with trisomy 13 mosaicism (n = 5) was 80% and for those with partial trisomy 13 (Robertsonian translocations) (n = 17) was 29%. This study is based on the largest data set on Survival for live births with trisomy 18 and trisomy 13. Although Median Survival for these children is 2 weeks or less, about one in five survive for 3 months or more and about 1 in 12 survive for 1 year or more. We suggest that these Survival rates are used in counselling as well as the Median Survival Time.
Susan M Chang - One of the best experts on this subject based on the ideXlab platform.
-
Survival analysis in patients with glioblastoma multiforme predictive value of choline to n acetylaspartate index apparent diffusion coefficient and relative cerebral blood volume
Journal of Magnetic Resonance Imaging, 2004Co-Authors: Joonmi Oh, Susan M Chang, Roland G Henry, Andrea Pirzkall, Ying Lu, Xiaojuan Li, I Catalaa, William P Dillon, Sarah J NelsonAbstract:PURPOSE: To investigate the potential value of pre-external-beam radiation therapy (XRT) choline-to-NAA (N-acetylaspartate) index (CNI), apparent diffusion coefficient (ADC), and relative cerebral blood volume (rCBV) for predicting Survival in newly diagnosed patients with glioblastoma multiforme (GBM). MATERIALS AND METHODS: Twenty-eight patients with GBM were studied using in vivo proton magnetic resonance spectroscopic imaging (1H MRSI) and diffusion- and perfusion-weighted imaging after surgery but prior to XRT. Patients were categorized on the basis of their volumes of morphologic and metabolic abnormalities (volume of CNI > or = 2 and CNI values), normalized ADC (nADC), or rCBV values within the T1 contrast-enhancing and T2 regions. The Median Survival Time was compared. RESULTS: A significantly shorter Median Survival Time was observed for patients with a large volume of metabolic abnormality than for those with a small abnormality (12.0 and 17.1 months, respectively, P = 0.002). A similar pattern was observed for patients with a low mean nADC value compared to those with high mean nADC value within the T2 region (11.2 and 21.7 months, respectively, P = 0.004). A shorter Median Survival Time was also observed for patients with contrast-enhancing residual disease than for those without the presence of contrast enhancement with marginal significance. CONCLUSION: The pre-XRT volume of the metabolic abnormality and the nADC value within the T2 region may be valuable in predicting outcome for patients with GBM.
-
Survival analysis in patients with glioblastoma multiforme predictive value of choline to n acetylaspartate index apparent diffusion coefficient and relative cerebral blood volume
Journal of Magnetic Resonance Imaging, 2004Co-Authors: Joonmi Oh, Susan M Chang, Roland G Henry, Andrea Pirzkall, Ying Lu, Xiaojuan Li, I Catalaa, William P Dillon, Sarah J NelsonAbstract:Purpose To investigate the potential value of pre-external-beam radiation therapy (XRT) choline-to-NAA (N-acetylaspartate) index (CNI), apparent diffusion coefficient (ADC), and relative cerebral blood volume (rCBV) for predicting Survival in newly diagnosed patients with glioblastoma multiforme (GBM). Materials and Methods Twenty-eight patients with GBM were studied using in vivo proton magnetic resonance spectroscopic imaging (1H MRSI) and diffusion- and perfusion-weighted imaging after surgery but prior to XRT. Patients were categorized on the basis of their volumes of morphologic and metabolic abnormalities (volume of CNI ≥ 2 and CNI values), normalized ADC (nADC), or rCBV values within the T1 contrast-enhancing and T2 regions. The Median Survival Time was compared. Results A significantly shorter Median Survival Time was observed for patients with a large volume of metabolic abnormality than for those with a small abnormality (12.0 and 17.1 months, respectively, P = 0.002). A similar pattern was observed for patients with a low mean nADC value compared to those with high mean nADC value within the T2 region (11.2 and 21.7 months, respectively, P = 0.004). A shorter Median Survival Time was also observed for patients with contrast-enhancing residual disease than for those without the presence of contrast enhancement with marginal significance. Conclusion The pre-XRT volume of the metabolic abnormality and the nADC value within the T2 region may be valuable in predicting outcome for patients with GBM. J. Magn. Reson. Imaging 2004;19:546–554. © 2004 Wiley-Liss, Inc.
-
phase ii study of high central dose gamma knife radiosurgery and marimastat in patients with recurrent malignant glioma
International Journal of Radiation Oncology Biology Physics, 2002Co-Authors: David A Larson, Vernon Smith, Kathleen R Lamborn, William M Wara, Penny K Sneed, Michael D Prados, Susan M Chang, Kelly M Nicholas, Daniel Devriendt, Sandeep KunwarAbstract:Abstract Purpose: To assess the outcome of high central dose Gamma Knife radiosurgery plus marimastat in patients with recurrent malignant glioma. Methods and Materials: Twenty-six patients with recurrent malignant glioma were enrolled in a prospective Phase II study between November 1996 and January 1999. The radiosurgery dose was prescribed at the 25–30% isodose surface to increase the dose substantially within the tumor's presumably hypoxic core. Marimastat was administered after radiosurgery to restrict regional tumor progression. Survival was compared with that of historical patients treated at our institution with standard radiosurgery. Results: The Median Times to progression after radiosurgery for Grade 3 and 4 patients was 31 and 15 weeks, respectively. The corresponding Median Survival Time after radiosurgery was 68 and 38 weeks. The Median Survival Time after radiosurgery in the historical patients was 59 and 44 weeks. Conclusion: The dual strategies of using high central dose radiosurgery to overcome tumor hypoxia together with marimastat to inhibit local tumor invasion may offer a small Survival advantage for recurrent Grade 3 tumors; they do not offer an advantage for recurrent Grade 4 tumors.